BIOCURE TECHNOLOGY INC. (1WH) - Total Assets
Based on the latest financial reports, BIOCURE TECHNOLOGY INC. (1WH) holds total assets worth €2.01 Million EUR (≈ $2.35 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 1WH operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
BIOCURE TECHNOLOGY INC. - Total Assets Trend (2021–2025)
This chart illustrates how BIOCURE TECHNOLOGY INC.'s total assets have evolved over time, based on quarterly financial data. See BIOCURE TECHNOLOGY INC. net assets for net asset value and shareholders' equity analysis.
BIOCURE TECHNOLOGY INC. - Asset Composition Analysis
Current Asset Composition (December 2025)
BIOCURE TECHNOLOGY INC.'s total assets of €2.01 Million consist of 2.3% current assets and 97.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.1% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how BIOCURE TECHNOLOGY INC.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 1WH stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BIOCURE TECHNOLOGY INC.'s current assets represent 2.3% of total assets in 2025, a decrease from 51.4% in 2021.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2025, down from 3.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
BIOCURE TECHNOLOGY INC. Competitors by Total Assets
Key competitors of BIOCURE TECHNOLOGY INC. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
BIOCURE TECHNOLOGY INC. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.10 | 0.04 | 0.07 |
| Quick Ratio | 0.10 | 0.04 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-389.54K | €-575.21K | €-367.60K |
BIOCURE TECHNOLOGY INC. - Advanced Valuation Insights
This section examines the relationship between BIOCURE TECHNOLOGY INC.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.03 |
| Latest Market Cap to Assets Ratio | 0.48 |
| Asset Growth Rate (YoY) | 1.0% |
| Total Assets | €2.01 Million |
| Market Capitalization | $960.84K USD |
Valuation Analysis
Below Book Valuation: The market values BIOCURE TECHNOLOGY INC.'s assets below their book value (0.48x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: BIOCURE TECHNOLOGY INC.'s assets grew by 1.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BIOCURE TECHNOLOGY INC. (2021–2025)
The table below shows the annual total assets of BIOCURE TECHNOLOGY INC. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.01 Million ≈ $2.35 Million |
+0.99% |
| 2024-12-31 | €1.99 Million ≈ $2.33 Million |
+0.75% |
| 2023-12-31 | €1.98 Million ≈ $2.31 Million |
-5.15% |
| 2022-12-31 | €2.08 Million ≈ $2.44 Million |
-49.83% |
| 2021-12-31 | €4.15 Million ≈ $4.86 Million |
-- |
About BIOCURE TECHNOLOGY INC.
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T … Read more